Johnson & Johnson’s stock surge raises the $300 question, even as earnings and litigation add friction

Johnson & Johnson is again drawing attention from traders and analysts who are asking whether the stock can reach $300 this year, after a sizable run-up. According to a recent market recap, the shares were up about 13.7% year to date and roughly 55% over the prior 12 months, helped by a mix of oncology strength and MedTech momentum highlighted by company leadership.

In remarks attributed to CEO Joaquin Duato, Johnson & Johnson framed the early part of 2026 as strong execution, saying the company is delivering on its promise for “a year of accelerated growth and impact.” The framing matters because getting the market to look through near-term volatility typically requires evidence that growth is broadening across portfolios and not just concentrated in a few late-cycle launches.

The same recap also points to why the stock has cooled from its highs. It cites a May pullback, with shares up only about 3.3% over the past week and around 4.2% over the past month. It further links recent pressure to reported quarterly results, saying Q1 2026 net income fell 52.4% year over year, driven in part by $330 million in litigation charges.

On the fundamentals side, the post attributes another key drag to biosimilar competition for STELARA. It states that STELARA biosimilar erosion contributed to the decline, and that the erosion effect weighed on earnings even as other parts of the business supported the broader narrative. For investors, the practical issue is timing: pipeline and franchise durability can be less immediately visible in a single quarter, while biosimilar losses hit revenue and profit trends right away.

The report also flags several potential overhang items that can complicate valuation. It mentions an FDA early alert on Abiomed catheter kits, and it references ongoing talc litigation testimony. The combined effect is a familiar one for large-cap pharma and MedTech companies: even when business performance is improving, legal and regulatory headlines can keep investors from paying up for a higher multiple.

Against that backdrop, the $300 target becomes a math problem as much as a story problem. The recap says the stock was around $232.77 at the time of writing, so moving to $300 would require a gain of about 28.9%. It also provides a valuation bridge using forward earnings expectations, arguing that a $300 share price would imply a forward price-to-earnings multiple of about 26 times versus its base case level nearer 22 times, meaning the more optimistic scenario would likely need additional multiple expansion beyond earnings growth.

The article further notes that analyst expectations are not uniform, with a consensus target described at $252.87 and a split of ratings. While the post argues the Street may be anchoring too cautiously, it stops short of offering a single guaranteed catalyst. In short, the debate is whether upcoming updates will be strong enough to justify a higher valuation range despite near-term earnings noise and the company’s disclosure of legal and regulatory matters.

For investors watching J&J, the near-term question is what updates will do the most work: whether upcoming results show earnings stabilization after litigation charges and biosimilar erosion, and whether regulatory matters around Abiomed remain contained. The other watch item is whether talc-related developments reduce uncertainty enough to broaden the market’s willingness to value the shares higher. Until then, the market’s ability to move the stock to $300 appears conditional rather than assured.